• Popular
    • Medicine
    • Radiology
    • Cardiology
    • Surgery
    • Nanomedicine
    • Military Medicine
    • Rehab
  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS
  • Submit PR
  • Log in
Medgadget
Medgadget
  • Popular
    • Medicine
      Biomimetic Construct Models Burn Injuries

      Biomimetic Construct Models Burn Injuries

      Moving Cells Using Ultrasound

      Moving Cells Using Ultrasound

      Smartphone Photos to Detect Anemia

      Smartphone Photos to Detect Anemia

      Ultrasound Catheter to Treat Hypertension

      Ultrasound Catheter to Treat Hypertension

    • Radiology
      Imaging Technique Reveals Contraction Patterns During Labor

      Imaging Technique Reveals Contraction Patterns During Labor

      Moving Cells Using Ultrasound

      Moving Cells Using Ultrasound

      Ultrasound Catheter to Treat Hypertension

      Ultrasound Catheter to Treat Hypertension

      Antibacterial Smart Sutures Visible in CT Scans

      Antibacterial Smart Sutures Visible in CT Scans

    • Cardiology
      Scientists Grow Electrodes Inside The Body

      Scientists Grow Electrodes Inside The Body

      Patient-Specific Soft Robotic Heart Replicas for Treatment Planning

      Patient-Specific Soft Robotic Heart Replicas for Treatment Planning

      Tiny Patch for Cardiac Ultrasound Imaging

      Tiny Patch for Cardiac Ultrasound Imaging

      Belt Monitors Heart Failure Patients

      Belt Monitors Heart Failure Patients

    • Surgery
      Biomimetic Construct Models Burn Injuries

      Biomimetic Construct Models Burn Injuries

      Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

      Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

      Self-Assembling Peptides as a Bioink

      Self-Assembling Peptides as a Bioink

      3D Bioengineered Skin Grafts Fit Complex Anatomy

      3D Bioengineered Skin Grafts Fit Complex Anatomy

    • Nanomedicine
      Bottlebrush Particle for Synergistic Drug Combinations

      Bottlebrush Particle for Synergistic Drug Combinations

      Extra Hot Nanoparticles for Cancer Therapy

      Extra Hot Nanoparticles for Cancer Therapy

      Making Tumors Tastier for the Immune System

      Making Tumors Tastier for the Immune System

      Improved Membrane Coating for Anti-Cancer Nanoparticles

      Improved Membrane Coating for Anti-Cancer Nanoparticles

    • Military Medicine
      Device Measures Hemoglobin More Accurately in Dark Skin

      Device Measures Hemoglobin More Accurately in Dark Skin

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fingertip Sensor Measures Lithium Levels in Sweat

      Fabric Makes Electricity from Movement to Power Wearables

      Fabric Makes Electricity from Movement to Power Wearables

      Wearable Uses Microneedles to Track Metabolism

      Wearable Uses Microneedles to Track Metabolism

    • Rehab
      Empowering Stroke Survivors: Interview with Kirsten Carroll, General Manager at Kandu Health

      Empowering Stroke Survivors: Interview with Kirsten Carroll, General Manager at Kandu Health

      Smart Walking Stick for Visually Impaired People

      Smart Walking Stick for Visually Impaired People

      Implantable Device Adheres to Muscle, Treats Atrophy

      Implantable Device Adheres to Muscle, Treats Atrophy

      Non-Invasive Spinal Modulation for Cerebral Palsy

      Non-Invasive Spinal Modulation for Cerebral Palsy

  • Categories
    • Exclusive
    • A-D
      • Anesthesiology
      • Art
      • Cardiac Surgery
      • Cardiology
      • Critical Care
      • Dentistry
      • Dermatology
      • Diagnostics
    • E-I
      • Emergency Medicine
      • ENT
      • Genetics
      • Geriatrics
      • GI
      • Informatics
    • M-N
      • Medicine
      • Military Medicine
      • Nanomedicine
      • Net News
      • Neurology
      • Neurosurgery
      • Nuclear Medicine
    • O-P
      • Ob/Gyn
      • Oncology
      • Ophthalmology
      • Orthopedic Surgery
      • Pathology
      • Pediatrics
      • Plastic Surgery
      • Psychiatry
      • Public Health
    • R-V
      • Radiation Oncology
      • Radiology
      • Rehab
      • Reproductive Medicine
      • Space Medicine
      • Sports Medicine
      • Surgery
      • Thoracic Surgery
      • Urology
      • Vascular Surgery
  • SUBSCRIBE
  • Submit PR
  • About
  • Log in
  • Submit PR
  • Follow
    • Facebook
    • Twitter
    • Linkedin
    • Youtube
    • Instagram
    • RSS

Eyevensys Non-Viral Gene Therapy for Ocular Diseases: Interview with Patricia Zilliox, CEO of Eyevensys

November 12th, 2019 Conn Hastings Exclusive, Genetics, Ophthalmology

Eyevensys, a clinical-stage biotechnology company based in France, has developed a method to perform non-viral gene therapy in the eye, with the aim of treating ocular diseases. The system uses ocular electrotransfection to deliver therapeutic genes into the eye. Consisting of an ocular device and an electrical pulse generator, the system can deliver DNA plasmids into the ciliary muscle. The idea is that the transfected cells in the eye allow for sustained local production of therapeutic proteins, which can then produce effects in a variety of structures in the eye, including the retina and choroid.

To date, the company has tested its system in treating non-infectious uveitis, an inflammatory condition in the eye that can lead to vision impairment. One of the major cytokines involved in the ocular inflammatory process is tumor necrosis factor alpha (TNFα). The treatment involves delivering genetic material (a plasmid) that encodes for an anti-TNFα protein.

On October 10th, Eyevensys presented results from its phase I/II clinical study of its gene therapy in non-infectious uveitis patients at the Annual Ophthalmology Innovation Summit in San Francisco. The trial included patients with late-stage non-infectious uveitis, and those treated using the gene therapy showed improvements in vision and macular edema up to 6 months after just one treatment.

The treatment did not elicit any serious adverse effects in the patients, and overall it was well tolerated. Eyevensys is also investigating the potential to deliver genes that encode for other proteins with utility in a variety of ophthalmic diseases, such as glaucoma and retinitis pigmentosa.

Medgadget had the opportunity to talk to Patricia Zilliox, CEO of Eyevensys, to discuss the technology.

Conn Hastings, Medgadget: Please give us an overview of the limitations of current treatments for ocular diseases.

Patricia Zilliox, Eyevensys: We see four key treatment approaches being used now for retinal diseases, and each of these have a variety of limitations, but some of the main issues are that treatments have a limited duration of any positive effect, they require frequent readministration or ongoing medical or lab monitoring, and in some cases there is a lack of full retinal exposure or poor ocular bioavailability of the treatment.

Our Electrotransfection System technology offers a long duration of protein expression, which keeps administration to a minimum. It’s also minimally invasive, so there’s less potential for an eye injury or any ocular side effects. We do this with non-viral vector plasmids, which can encode a variety of therapeutic proteins with a low risk of immunogenicity, so it’s less likely to generate an immune response.

Medgadget: Please give us some background on the Eyevensys non-viral gene therapy system. How does the system work?

Patricia Zilliox: Our technology is based on a two-part system, an Ocular Device and a Pulse Generator. We use these in tandem to deliver the DNA plasmids encoding for therapeutic proteins to the ciliary muscles. Once inside the ciliary muscle, the muscle becomes a production site, like a biofactory, and can start to produce the protein, and then these proteins travel to the retina at the back of the eye. We’ve validated this model in animals and observed efficacy in these pre-clinical studies for the treatment of uveitis, wet AMD and retinal degeneration.

Medgadget: What is it like for patients to undergo gene therapy using the system?

Zilliox: For patients, knowing that they can treat these conditions in a minimally invasive way can be a relief, especially when considering alternatives, such as ocular implants, or a treatment requiring multiple administrations. Additionally, we are really trying to improve therapeutic outcomes for these conditions, so the fact that patients are seeing continued visual improvement means that quality of life continues to improve for these patients, too, which is an important goal for us. This system, however, is not able to correct or edit gene mutations.

Medgadget: How long are the delivered genes expressed in the treated tissues?

Zilliox: In our phase I/II trial studied patients with advanced stages of disease, and based on the data from part 1 of the study, we saw therapeutic protein expression up to 8 months after treatment.

Medgadget: Please give us an overview of the recent phase I/II trial of the treatment in non-infectious uveitis.

Zilliox: The data we just presented are from part 1 of our phase I/II clinical safety study for EYS606, which is a non-viral vector that encodes an anti-TNFα protein. We had nine patients in the U.K. and in France that presented with late-stage non-invasive uveitis. We had three patient cohorts with three patients each with different dose levels for the three cohorts.

At the lowest dose, we observed more than 10 ETDRS letters of improvement in one patient, which is significant in uveitis, which can ultimately cause blindness. The highest dose resulted in two participants seeing +12 or more ETDRS letters of improvement. Based on these results, we are eager to move forward to the next part of this trial.

Medgadget: How do you see this type of technology developing? Are you planning any other trials for different ocular diseases in the future?

Zilliox: We expect to continue to develop this technology beyond just uveitis and potentially to apply it to other therapeutic targets. We have a robust preclinical pipeline that is looking at retinitis pigmentosa, dry AMD, and other conditions, and we are confident that the technology can handle so much more. We have an extensive patent portfolio on the electrotransfection technology as it applies to the eye, so there is much more to come on the R&D side from Eyevensys.

In terms of upcoming trials, we expect to stay focused for the moment on uveitis, so we’ll be continuing our clinical trial work with EYS606—we have part 2 of the phase I/II trial in the EU that we are set to launch, that will confirm the safety of the maximum tolerated dose and give us an initial sense of efficacy. We are also preparing to launch a phase 2 trial in the U.S. for the same therapy in development. We did receive IND clearance from FDA late August 2019. In this case, we will be testing our therapy in development against active chronic non-infectious uveitis, and we will look at administration closely, and the efficacy of one administration compared with two.

See a video below of the Eyevensys CEO Patricia Zilliox giving a presentation about the technology at the Ophthalmology Innovation & Investment Meeting in 2018.

Link: Eyevensys homepage…

Conn Hastings

Conn Hastings received a PhD from the Royal College of Surgeons in Ireland for his work in drug delivery, investigating the potential of injectable hydrogels to deliver cells, drugs and nanoparticles in the treatment of cancer and cardiovascular diseases. After achieving his PhD and completing a year of postdoctoral research, Conn pursued a career in academic publishing, before becoming a full-time science writer and editor, combining his experience within the biomedical sciences with his passion for written communication.

Sponsored
machineMD and Varjo revolutionize the diagnosis of brain disorders with a VR-based eye-tracking solution 

machineMD and Varjo revolutionize the diagnosis of brain disorders with a VR-based eye-tracking solution 

Ax-Surgi Hemostat gets FDA Clearance for Surgical Bleeding Control

Ax-Surgi Hemostat gets FDA Clearance for Surgical Bleeding Control

Clarius Report Finds 85% of Clinicians Believe Ultrasound Leads to Better Patient Outcomes

Clarius Report Finds 85% of Clinicians Believe Ultrasound Leads to Better Patient Outcomes

New AASLD Practice Guidance Calls for the Use of Noninvasive Liver Evaluations for Earlier Detection of NAFLD and NASH

New AASLD Practice Guidance Calls for the Use of Noninvasive Liver Evaluations for Earlier Detection of NAFLD and NASH

C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

interviews & reviews
Empowering Stroke Survivors: Interview with Kirsten Carroll, General Manager at Kandu Health

Empowering Stroke Survivors: Interview with Kirsten Carroll, General Manager at Kandu Health

Alpha TAU Killing Tumors With Highly Targeted Alpha Radiation

Alpha TAU Killing Tumors With Highly Targeted Alpha Radiation

Neuroimmune Modulation for Inflammatory Disease: Interview with Dr. Simhambhatla, President and CEO of SetPoint Medical

Neuroimmune Modulation for Inflammatory Disease: Interview with Dr. Simhambhatla, President and CEO of SetPoint Medical

Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Balance Boards to Stay Active in the Offfice: Interview with Joel Heath, CEO of FluidStance 

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Exciting Medtech at the Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

Medgadget Visits Healthcareᐩ Expo Taiwan

  • Subscribe
  • Contact us
  • Submit
  • About
  • Back to top
Medgadget

Medical technologies transform the world! Join us and see the progress in real time. At Medgadget, we report the latest technology news, interview leaders in the field, and file dispatches from medical events around the world since 2004.

  • About
  • Editorial policies
  • Contact
  • Terms of Service
  • Privacy
  • Submit press release
  • Advertise
© Medgadget, Inc. All rights reserved. | The Medical Revolution Will Be Blogged.
Please support this website by adding us to your whitelist in your ad blocker. Ads are what helps us bring you premium content! Thank you!
Posting....
  • Facebook
  • Twitter
  • LinkedIn
  • Reddit
  • Email